Glucocorticoids are beneficial in Duchenne muscular dystrophy (DMD). Osteopontin (OPN), the protein product of SPP1, plays a role in DMD pathology modulating muscle inflammation and regeneration. A polymorphism in the SPP1 promoter (rs28357094) has been recognized as a genetic modifier of DMD, and there is evidence suggesting that it modifies response to glucocorticoid treatment. The effect of the glucocorticoid deflazacort on SPP1 mRNA and protein expression was investigated in DMD primary human myoblasts and differentiated myotubes with defined rs28357094 genotype (TT versus TG). Both healthy and DMD myoblasts/myotubes abundantly express OPN. In immunoblot, OPN was detected as a doublet of 55 and 50 kDa bands, with a shift towards the lighter isoform in the transition from myoblasts to myotubes and to mature muscle. A significant increase in OPN expression was observed in DMD myotubes carrying the TG compared to the TT genotype at rs28357094. Deflazacort treatment led to a significant increase of OPN only in myotubes carrying the TG genotype, leading to OPN overexpression. Our study shows a strong effect of the rs28357094 G allele in increasing OPN expression in the presence of deflazacort, and adds to the evidence that rs28357094 polymorphism may predict response to glucocorticoids in DMD.
Introduction
Duchenne muscular dystrophy (DMD [MIM: 310200]) is an X-linked progressive neuromuscular disease caused by dystrophin deficiency due to truncating DMD gene mutations. Dystrophin plays a pivotal role in maintaining muscle fiber membrane integrity, and its deficiency results in dramatic muscle deterioration (1) . Recent studies of DMD patients and animal models have uncovered a role of osteopontin (OPN, [MIM: 166490] ) (2, 3) as a modulator of disease severity and progression. OPN is encoded by the SPP1 gene and is a member of the small integrin-binding N-linked glycoprotein family (4), first identified as an adhesive component of the extracellular matrix of the bone tissue. OPN is expressed in a wide range of cells, including epithelial cells, osteoblasts, osteoclasts, immune cells (especially macrophages and lymphocytes), and muscle cells. It is transcribed in five different isoforms due to alternative splicing, and can be secreted as a soluble cytokine or as a component of the extracellular matrix (ECM), while an intracellular form of the protein (iOPN) has been described in murine cells (5, 6) . OPN is extensively modified by glycosylation, phosphorylation, sulphation (6) , and proteolytic cleavages by thrombin and matrix metalloproteinases (MMPs) (7) , thus resulting in a complex variety of functionally distinct units. OPN is involved in a number of biological processes that include tissue repair, cancer, inflammation, and fibrosis (8) (9) (10) (11) (12) (13) .
In the context of muscle pathology, data from the animal models of DMD seem to be discordant. The ablation of SPP1 was shown to have beneficial effects in the standard mdx mouse; specifically, the double-mutant Spp1 negative mdx mouse (dmm) showed a diminished amount of intramuscular neutrophils and NKT-like cells, resulting in a decrease of TGF-ß-mediated signalling and fibrosis (14) . The same laboratory demonstrated a shift to a pro-regenerative macrophage phenotype in the dmm model (15) . On the other hand, very recently Calyjut et al. demonstrated that when transferring the mdx mutation to a different mouse strain, the new mdx 129/Sv animals showed a substantially milder phenotype than standard mdx, even though the former express Spp1 at markedly higher levels than the latter (16) . Despite the controversies on the beneficial or harmful effect of OPN in muscle dystropathology, it is clear that the Spp1 gene expression is strongly induced (up to 100-fold) after acute muscle damage (17) , and that OPN plays a relevant role both as a cytokine, by recruiting inflammatory cells (18) , and as a structural component of the nascent extracellular matrix surrounding regenerating myotubes (19, 20) . A single nucleotide polymorphism (SNP), 66 bp upstream the SPP1 starting codon (rs28357094), has been identified as a genetic modifier of weakness progression in DMD (2) and muscle size in healthy females (17) .
In particular, DMD patients carrying the G allele (TG or GG) showed reduced grip strength and earlier age at loss of ambulation (LoA) (21, 22) compared to patients homozygous for the T allele (TT). This association was validated in an independent DMD cohort, in which the G allele was associated with a more rapid decrease in the 6-min walk test performance (22) , but could not be reproduced in two other independent DMD cohorts (23, 24) . rs28357094 was shown to modulate OPN transcription efficiency in HeLa and muscle cells, the G allele being associated with reduced expression (19, 20) , but the rs28357094 genotype did not dictate any difference in SPP1 mRNA or OPN protein levels in DMD muscle biopsies (3). Thus, a discrepancy is evident between the mdx mice and human, as mice lacking OPN perform better, while DMD boys carrying the G allele, predicted to drive a less efficient SPP1 transcription (20) , are weaker.
A recent study, aiming to validate the association of the rs28357094 G allele with the early loss of ambulation in DMD, showed that the detrimental effect of this genotype was only observed in glucocorticoid-treated DMD patients (21) . These clinical studies, together with evidence that the SPP1 promoter can be modulated by steroid hormones (26) , suggest the hypothesis that rs28357094 might be a pharmacodynamic biomarker of glucocorticoid response in DMD, rather than a predictor of disease progression per se.
To further elucidate the role of rs28357094 genotype on OPN expression, we investigated OPN expression in skeletal muscle myoblasts and myotubes obtained from DMD patients and healthy controls, with defined rs28357094 genotypes. Moreover, we studied the effect of the glucocorticoid deflazacort (DFZ) on OPN expression in different rs28357094 genotypes, to verify the hypothesis that steroid-responsive elements in the SPP1 promoter region may predict response to glucocorticoid treatment.
Results

Human myoblasts, myotubes and skeletal muscles express OPN isoforms of different molecular weight
We compared OPN expression patterns in DMD proliferating cells, differentiated myotubes and muscle biopsies by western blot. As shown in Figure 1A ), OPN was detected as a single 55 kDa band in DMD myoblasts, as two distinct bands of approximately 55 and 50 kDa in differentiated DMD myotubes, and as a single 50 kDa band in muscle biopsies from DMD boys. The same expression pattern was observed in control myoblasts, myotubes, and muscles, while recombinant human OPN was observed at a molecular weight (MW) between 55 and 50 kDa (see Supplementary Material). We checked the specificity of both observed OPN bands by performing a transient siRNAmediated OPN silencing in differentiated myotubes, in which both 55 and 50 kDa bands were observed. After 6 days of differentiation, cultures were transiently transfected with siRNA oligonucleotides and collected 24h post transfection. Both 55 and 50 kDa bands were down-regulated to the same extent by two distinct siRNA sequences (Fig. 1B-D) , confirming that the observed bands were indeed the products of SPP1 gene translation. Since the presence of the two bands appeared to vary according to muscle maturation, throughout this work we quantified OPN protein both as individual bands and as the sum of both bands. Validation experiments with two alternative anti-OPN antibodies confirmed an OPN band at 55 kDa (Supplementary Material, Fig. S1 ).
Differentiation into myotubes increases both SPP1 transcript and 50 kDa OPN expression, more markedly in DMD primary cultures
In order to define if OPN is upregulated in DMD primary muscle cells as it is in DMD muscle biopsy samples (3), total SPP1 mRNA and OPN protein were isolated from eleven DMD myogenic cell lines and nine age-matched normal controls. Total SPP1 mRNA level, evaluated by RT-PCR, and OPN protein expression, evaluated by Western blot, were quantified in myoblasts ( Fig. 2A-D) and differentiated myotubes (Fig. 2E-H) . In myoblasts, no differences were observed in OPN expression between DMD and control cultures, neither at the transcript nor at the protein level. After differentiation, there was an increase of SPP1 mRNA in DMD cultures, although this was not statistically significant (paired Wilcoxon test ¼ 0.053, see Fig. 2A compared to 2E), and, as expected from the initial analyses described above, a significant increase in OPN expression evaluated by the 50 kDa band in both DMD and control cultures (P ¼ 0.021 and 0.015 respectively, see Fig. 2B compared to 2F). This increase was more marked in DMD cultures, although the Mann-Whitney test comparing the DMD vs. control myotubes was not significant. On the other hand, there were no significant changes in the expression of OPN evaluated as the 55 kDa band or both bands combined. Taken together, these results confirm that there is an increase in 50 kDa OPN expression after myotube differentiation, which might depend on increased SPP1 transcription, and be more pronounced in the dystrophin-deficient myogenic cells. However, in isolated myogenic cell cultures, we did not observe the dramatic upregulation of SPP1 transcript and OPN protein, that has been previously described in dystrophin-deficient muscle tissue (3, 17) .
OPN protein levels are influenced by rs28357094 genotype in differentiated DMD myotubes
To verify if genotype at the rs28357094 SNP in the SPP1 promoter predicts SPP1 mRNA and/or OPN levels, 11 DMD (7 TT, and 4 TG) and 9 age-matched normal myogenic cell lines (5 TT, and 4 TG) were stratified based on their genotype. In myoblasts, there were no significant differences between genotypes neither in SPP1 mRNA expression (Fig. 3A) nor in OPN protein expression evaluated as the 50 kDa band (Fig. 3B) . However, we observed a significantly higher 55 kDa and total OPN protein expression in rs28357094 'TT' myoblast cultures, compared to 'TG' (MannWhitney U test P ¼ 0.018 for 55 kDa, and P ¼ 0.003 for total, Fig. 3 (C , and D). When considering DMD cultures only, this difference remained statistically significant for total OPN (P ¼ 0.018), but not for 55 kDa OPN (P ¼ 0.07). Interestingly, the situation seemed to be inverted in myotubes, where the TT genotype, compared to TG, was associated to significantly reduced 55 kDa and total OPN expression (P ¼ 0.0043 and 0.018 respectively, Fig. 3 , (G and H). The genotype difference in 55 kDa OPN expression remained significant, when considering DMD cultures only (P ¼ 0.01).
In myotubes, there were no other significant differences in SPP1 mRNA or 50 kDa OPN expression between genotypes ( Fig. 3 , (E and F).
Dystrophin deficiency and rs28357094 TG genotype may increase glucocorticoid responsiveness of the SPP1 promoter
To test if DFZ treatment modulates SPP1 mRNA or OPN protein in DMD myoblasts and myotubes, and if this response is modified by SPP1 rs28357094 genotype, RT-PCR analysis and western blotting analyses were performed in DMD and control cell lines treated with 0.1 lM and 1 lM DFZ; results were then stratified by SPP1 genotype. In myoblasts, DFZ treatment did not modify SPP1 mRNA expression in control cultures. The same was true for DMD cultures from patients carrying the TT genotype, while a non-significant increase in transcript quantity was noted with in DFZ-treated DMD cultures from patients carrying the TG genotype (repeated measures ANOVA P ¼ 0.058, Fig. 4A ). In myotubes, baseline levels of SPP1 mRNA expression were slightly higher, especially in DMD and rs28357094 TG samples, as stated above. When DFZ was added to the culture, there appeared to be a slight, non-significant decrease in control cultures, while DMD cultures showed slightly increased transcription levels, especially for TG samples, albeit with high variability and no statistically significant correlations (Fig. 4E) . 
Effect of deflazacort treatment and OPN protein expression as a function of rs28357094 genotype
We then analyzed changes in OPN protein expression in myogenic cell cultures treated with DFZ. In myoblasts, the 50 kDa OPN band was detected at low levels at baseline, except in DMD cultures carrying the TT genotype which showed higher levels. In this subgroup, the 50 kDa band intensity decreased slightly, although not significantly, with increasing concentration of DFZ (Fig. 4, panel B) . Conversely, DMD 'TG' cultures showed an increase of 50 kDa band intensity at 1 lM DFZ, which was significant in the repeated measures ANOVA model for increasing DFZ concentration (P ¼ 0.012, Fig. 4 , panel B). The 55 kDa band of OPN and total OPN showed a slight decrease with increasing DFZ concentrations in all subgroups, which was statistically significant only in control samples carrying the TT genotype for both 55 kDa and total OPN (repeated measures ANOVA P ¼ 0.038 and 0.033 respectively, Fig. 4 , panels C and D). In myotubes, expression of the low molecular weight band was higher as stated above, but we did not observe any significant effects of increasing DFZ concentrations on OPN protein quantity, assessed by either OPN band or as a whole, in any of the subgroups, although DMD 'TG' cultures did show the highest average intensity of the both 50 and 55 kDa OPN band with 1 lM DFZ (Fig. 4 , panels F to H). With 1 lM DFZ treatment, total OPN was higher in DMD myotubes carrying the TG, rather than TT genotype (P ¼ 0.047). Representative Western blots for the different groups are shown in Figure 4I -L, and all blots used for quantitation are available as Supplementary Material.
Multivariate analysis confirms the concurrent effect of dystrophin deficiency and rs28357094 genotype in increasing glucocorticoid responsiveness of the SPP1 promoter
Taken together, the results presented above suggest that osteopontin expression in myogenic cells, at the transcript and protein level, is influenced by the complex interaction of several factors: muscle cell maturation, dystrophin deficiency, rs28357094 genotype, and glucocorticoid (DFZ) treatment. In order to dissect independent and concurrent effects of these variables on the outcomes of interest (SPP1 transcript and OPN protein bands), we devised a repeated measures ANCOVA model evaluating the correlation of outcomes with different DFZ concentrations, with covariates for dystrophin deficiency and rs28357094 genotype, and interaction terms between covariates, in both myoblast and myotube cultures ( Table 1 ). The ANCOVA analysis of SPP1 mRNA expression in myoblasts showed significant interaction with rs28357094 genotype for both dystrophin deficiency and DFZ concentration (P ¼ 0.029 and 0.020 respectively). This interaction is driven by the DFZinduced, dose-dependent mRNA increase in DMD 'TG' samples ( Fig. 4A) . Again in myoblasts, the ANCOVA analysis of OPN protein band intensity showed strong significant independent effects of rs28357094 genotype on 55 kDa and total OPN (P ¼ 0.001 and 0.0005 respectively), corresponding to the increased 55 kDa and total OPN band intensity in Western blots from 'TT' cultures at baseline (Fig. 3 C and D) . The very low intensity of the 55 kDa OPN band in myoblasts accounts for similar findings in 55 kDa and total OPN. In myotubes, dystrophin deficiency had a significant, independent effect in increasing SPP1 transcript (P ¼ 0.029, see Fig. 2E ), while the independent effects of rs28357094 on 55 kDa and total OPN protein quantity were barely significant (P ¼ 0.050 and 0.048 respectively), although these effects were in the opposite direction as observed in myotubes (see Fig. 3 , panels G and H, as opposed to panels C and D). Furthermore, the complex interaction terms of all three covariates (dystrophin deficiency, rs28357094 genotype, and DFZ concentration), was significant in the ANCOVA analysis of 50 kDa and total OPN in myotubes (P ¼ 0.033 and 0.041, respectively).
Discussion
The role of genetic modifiers of DMD is becoming increasingly interesting given the potentially relevant implications they have for the selection of homogeneous groups of patients, deeper knowledge of the pathophysiology of dystrophin deficiency, and planning of novel therapeutic strategies. The availability of genotyping chips and next generation sequencing (NGS) techniques has allowed genome-wide study of genetic variations in large populations in a cost-effective and highly efficient way (27) . However, once novel associations are established between SNPs and disease phenotypes, we are faced with the problem of linking genetic variation to protein function in the context of cellular molecular mechanisms (28) . Osteopontin as a DMD modifier epitomizes this challenge. The discovery that a single nucleotide polymorphism (SNP) in the promoter region of the SPP1 gene is able to modify muscle strength in DMD (2) has represented the proof-of-principle that genetic modifiers have a role in DMD disease progression, but it also raised several questions that still await for a definitive answer: is osteopontin secretion damaging or beneficial in the dystrophic muscle microenvironment? Is the transcriptional effect of the polymorphism the actual disease-modifying mechanism? And is SPP1 genotype a modifier of disease progression, or of response to treatments? In this study, we started to dissect the complex molecular mechanisms underlying the effect of SPP1 genotype on ostepontin protein expression, and the effect of steroid treatment in different SPP1 genetic backgrounds, to explain some of the observed variability in DMD disease progression.
First of all, our results suggest that OPN expression may be developmentally regulated in muscle. In particular, OPN was identified in proliferating myoblasts as a 55 kDa band, in differentiated myotubes as both a 55 and a 50 kDa band, and in mature muscle as a single 50 kDa band. Gene silencing experiments, targeted to SPP1, confirmed that both observed bands correspond to osteopontin isoforms. A certain degree of variability in the ratio between the two bands was observed in the experimental setting. We suppose that this variability may be in part related to the various percentages of non-myogenic cells present in each cell line (29) and in part to the degree of myoblasts differentiation to myotubes (30) . Even if, cell cultures were enriched in CD56 positive cells (31) in order to minimize these confounding factors, some contaminating fibroblasts may have escape selection and be responsible of the observed variability. It is hard to predict if the observed different molecular weight OPN bands arise from SPP1 splicing isoforms, from different post-translational modifications, or a combination of the two. It is well known that the SPP1 transcript is subject to alternative splicing generating different isoforms that show specific expression and roles in different cell contexts (6, 32) , and this also applies to skeletal muscle (33) . The molecular weights reported for splicing isoform OPN-a and OPN-b (54 kDa and 50 kDa, respectively) (33) are close to those of the observed bands, and unpublished data from our laboratory show a high-level expression of both OPN-a (full length) and OPN-b (D exon 5) transcripts in human myoblasts. However, fully dissecting OPN isoform expression in muscle is beyond the purpose of this paper. Furthermore, OPN is subject to extensive post-translational modifications by glycosylation, phosphorylation, and sulphation, and possibly also by cross-linking and proteolytic cleavage (19) .
To add to the hypothesis of a regulation of osteopontin during development, in DMD cultures, we observed an increase of SPP1 mRNA and of the 50 kDa OPN isoform when shifting from myoblasts to myotubes. These modifications were observed also, albeit to a lesser extent, in control muscle cultures. However, the differential expression in transcription and translation of osteopontin between normal and DMD cultured cells did not match the definite overexpression of ostepontin observed in DMD muscle tissue compared to controls (3, 34, 35) . The developmental shift in OPN molecular weight, regardless of its actual molecular basis, might reflect the shift between different biological roles of OPN, first as a chemotactic cytokine in the acute phase of inflammation, and then as a regenerationenhancing matricellular protein (18, 19) .
As a model system, we used DMD proliferating myoblasts and differentiated myotubes. While this model offers several advantages, such as the use of cells from patients with definite SPP1 genotypes and the possibility to manipulate the physicochemical environmental, an important drawback is represented by the lack of stress-induced muscle damage, and its downstream consequences. DMD pathophysiology is the direct consequence of dystrophin deficiency in muscle fibers, resulting in muscle fiber fragility and contraction-mediated injury, and leading to asynchronous cycles of segmental necrosis and regeneration, which are at first effective but eventually fail and give way to fibrosis (36, 37) . Contraction-induced sarcolemma rupture triggers a variety of molecular changes including release of mitogenic factors (38) (39) (40) , cytokines (41) , and reactive inflammatory signature molecules (20, 42) that modify the muscle microenvironment. Since osteopontin is induced by skeletal muscle injury (17, 18, (43) (44) (45) , and muscle cells remain intact in cell culture, we feel that the reduced overexpression of OPN in myoblasts and myotubes is probably due to the lack of the cascade of events triggered by the muscle damage itself. Moreover, since osteopontin is also secreted from infiltrating macrophages in the foci of muscle cell degeneration (14, 20) , the lack of inflammatory cells in our model may be an important factor in explaining the lack of OPN overexpression we found in cultured DMD cells compared to in vivo findings.
Another intriguing issue is the role of the rs28357094 single nucleotide polymorphism in gene transcription/translation, and how these events are in turn capable to modulate DMD phenotype expression. In vitro SPP1 transcription studies (25, 26) predict that DMD patients carrying the more common TT genotype at rs28357094, who lose ambulation later and show a greater grip strength compared to TG/GG patients (2,21), should have higher SPP1 promoter activation, and hence higher osteopontin levels in muscle. However, rs28357094 genotype did not correlate with either the level of SPP1 mRNA or the amount of OPN protein in DMD muscle biopsies, taken at diagnosis prior to any treatment (3).
In DMD proliferating myoblasts, we did not observe any difference between genotypes in SPP1 mRNA expression, but we found a significant overexpression of the 55 kDa OPN band in cells carrying the TT genotype compared to TG. This result is in line with in vitro transcriptional activity studies of the SPP1 gene in different rs28357094 genotypes (25, 26) and with the hypothesized developmental role of the OPN molecular weight transition, that predicts a greater expression of the higher molecular weight band in the early phases of myoblast proliferation. In differentiating myotubes, the downregulation of the 55 kDa band in the TT genotype fits with this hypothesis. On the other hand, the expected upregulation of the 50 kDa band in TT DMD culture did not reach significance because of a very large standard deviation. However, the TT myotubes displayed the highest level of osteopontin compared to TG.
Glucocorticoids are beneficial in DMD (46, 47) , and are considered standard of care in the management of the disease. More importantly, they are the only medication available to all DMD patients regardless of their specific DMD gene mutation, and at present, the most diffusely prescribed treatment in DMD. It has been shown that the effect of rs28357094 in DMD is enhanced by glucocorticoids (21, 23) , and it has been proposed that osteopontin may be envisaged as a pharmacodynamic modifier of glucocorticoid response in DMD (2, 21) . Among steroids, deflazacort (DFZ) is emerging as potentially more effective (21) and more tolerable than prednisone (48, 49) , but with both these drugs response to treatment is variable, some patients showing greater clinical benefit than others. Molecular bases of this differential efficacy of steroids are largely unknown. In this study, we treated both proliferating myoblasts and differentiating myotubes, carrying different SPP1 rs28357094 genotypes, with two DFZ regimens (low and high dosage), to verify if osteopontin has a role in steroid response in DMD. In both myoblasts and myotubes, SPP1 mRNA levels were higher in the TG than TT genotype, although with high variability in the data. A multivariate analysis, taking in account the concurrent effect of dystrophin deficiency and rs28357094 genotype, showed a significant interaction. These results are in line with the hypothesis that glucocorticoid receptor elements (GREs) are active in the promoter region of the SPP1 gene (26) . The rs28357094 polymorphism is located in the SPP1 promoter region, 66 bp upstream of the transcription start, and it has been shown to modify the binding affinity for the SP1 transcription factor (25) . In DFZ-treated cells with a TT genetic background the SPP1 gene transcription is driven by SP1, whereas in TG cells, where the G polymorphism interferes with the binding of SP1 (25), the GRE elements, activated by DFZ, may promote a very efficient and sustained gene transcription. The role of enhancer elements in the SPP1 promoter has been already hypothesized to explain the rs28357094 female-specific genotype effect in modifying muscle size in female adult volunteers (17, 26) . Allele-specific reporter assays in vitro showed that the G allele responds to estrogen treatment with a 3-fold increase in luciferase activity compared to untreated cells, likely due to the interaction between estrogen enhancer elements and the more proximal SP1 transcription factor site (26) . A limit of our experimental approach, that could potentially affect sensitivity, is the dominant genotype model. Due to the scarce availability of GG genotype muscle cell, we compared homozygous TT cells with heterozygous TG. While the modifier function of the SNP was observed in DMD populations as a dominant effect, at the molecular level homozygous GG cells might present a clearer SNP effect. When switching from transcript to OPN protein level analyses, DFZ effects become more intricate. In TG genotype myoblasts, the 55 kDa OPN band showed no changes with DFZ treatment, while the 50 kDa OPN band, expressed at low level in myoblasts, resulted significantly increased with treatment. This is in line with the model of a G-allele specific upregulation of OPN by glucocorticoids. Conversely, in TT myoblasts, the 55 kDa OPN band showed a significant decrease in DFZ-treated cells. Trajectories in OPN protein expression, after DFZ treatment, did not show significant modifications in myotubes, although those with the TG genotype showed the highest average intensity of the 50 kDa OPN band. The complex interaction among dystrophin deficiency, rs28357094 genotype and DFZ concentration was significant in multivariate analysis for myotubes. Thus, it seems that DFZ treatment led to a significant decrease of OPN in TT myoblasts and myotubes, whereas TG cells showed subtle changes. The finding that SPP1 mRNA expression does not exactly predict OPN protein expression levels may be related to post-transcriptional and post-translational regulatory steps (19) , or to limits of our study design, that did not measure secreted OPN in the culture medium, leaving the possibility that DFZ treatment may affect the amount of the soluble protein.
Taken together, our data suggest that OPN transcription and protein synthesis are influenced by DFZ treatment and that the effect of DFZ is fine-tuned by rs28357094 genotype and dystrophin absence in primary human muscle cells.
Given the results of this study, our unifying model to explain the effect of SPP1 rs28357094 in modulating phenotype expression in DMD postulates as follows. Lack of dystrophin in skeletal muscle fibers induces osteopontin expression both by muscle cells and by infiltrating inflammatory cells (19) . While osteopontin is beneficial to DMD muscle in the early phases of the regenerative events that follows muscle injury (18) , its chronic overexpression may hinder regeneration (50) . Indeed, osteopontin expression in skeletal muscle is strictly regulated in time: it is induced approximately 100-fold within 1 day after muscle injury, it remains expressed at high level during regeneration, and falls back to baseline by 16 days, when regeneration is complete (17) . The upregulation of SPP1 transcript and OPN observed in our experiments recapitulate these phenomena in the myogenic cell cultures. In a SPP1 rs28357094 TG genetic background, glucocorticoids, through activation of GRE elements, interfere with the physiological SP1-mediated activation of the promoter, and result in chronic ostepontin overexpression. In this scenario, disregulated SPP1 expression may add to the desynchronization of damage-related gene expression patterns in dystrophic muscle, which has been shown to be a driver of failed regeneration and fibrosis (51) .
Further research is needed to better understand the role of specific OPN isoforms, the various post-translational modifications of the protein, and the effects of steroids in the various SPP1 genetic backgrounds, which might also be relevant to inflammatory diseases beyond DMD. 
Materials and Methods
Ethics approval
Patients
Eleven subjects were selected from a cohort of DMD patients followed at the Neuromuscular Center of the University of Padova. All patients showed total absence of dystrophin in skeletal muscle and/or out-of-frame or nonsense DMD mutations. Mean age at biopsy 6 standard deviation was 3.7 6 2.3 years. DNA samples were obtained after informed consent. Nine normal pediatric muscle biopsies were used as controls (mean age at biopsy 6 standard deviation 6.8 6 5.1 years). Patients' muscle biopsies were obtained at the time of diagnosis, prior to any steroid treatment.
Cell isolation, culture and differentiation
Human muscle biopsies from patients and healthy controls were collected, minced into small pieces and placed in a solution of 0.8% w/v collagenase I (Life Technologies; Carlsbad, CA, USA) in DMEM, supplemented with 100 U/ml penicillin, 100 mg/ ml streptomycin (Life Technologies; Carlsbad, CA, USA), for 60 min. After digestion, muscle fragments were gently dissociated by pipetting with a 2 ml and 1 ml pipette, before being passed through a 21 G syringe needle for 20-25 times. Two volumes of growth medium (see below) were added to the digestion mix and the resulting cell suspension was centrifuged for 10' at 300g . The resulting pellet was eventually resuspended and plated on a matrigel-coated 35 mm well in growth medium composed of 20% FBS, 25 ng/ml hFGFb (human Basic Fibroblast Growth Factor, Immunotools; Friesoythe, Germany) in Ham's F12 medium (Euroclone; Milan, Italy) with Pen/Strep. Cells were expanded for 2-3 passages in 60 and 100 mm dishes. Examples of the cultures are shown in Supplementary Material, Figure S2 .
Isolation of CD56þ cells
Cell cultures obtained by enzymatic and mechanical disruption of muscle fragments were further enriched in CD56 positive cells (CD56þ), as a bona fide marker of myogenic cells. Cells were detached in citrate buffer (14.5 mM trisodium citrate, 134 mM KCl) in order to preserve the surface proteins, collected, bound to the CD56 MACS microbeads and separated with the MACS Columns (Miltenyi Biotec; Bologna, Italy), as described in the supplier protocol. CD56þ cells were re-plated on gelatin-coated dishes, expanded and used for further experiments within for 2-8 passages. When needed differentiation into myotubes was achieved by exposing confluent cultures to a differentiation medium composed of 2% horse serum, 30 lg/ml insulin and Pen/Strep in DMEM for 7 days.
Single nucleotide polymorphism (SNP) genotyping rs28357094 genotyping was performed using amplification refractory mutation system polymerase chain reaction method (ARMS-PCR) and then confirmed by Applied Biosystems TaqMan SNP genotyping assays and end-point allelic discrimination on an ABI-7000 SDS instrument. Primers and PCR conditions are available upon request. Proliferating myoblasts or differentiating myotubes were treated with vehicle (untreated cells), 0.1 mM or 1 mM DFZ for 3 days, then cells were lysed for western blotting or RNA extraction.
Deflazacort (DFZ) treatment
Real-time PCR analysis
Total RNA was isolated from myoblasts and myotubes using Trizol (Life Technologies; Carlsbad, CA, USA). For all conditions, 1mg of total RNA was reverse-transcribed to cDNA according to the protocol of SuperScript III Reverse Transcriptase (Life Technologies; Carlsbad, CA, USA). Transcript levels were measured using SYBR Green Real-Time PCR (Applied Biosystem; Foster City, CA, USA) using the ABI PRISM 7000 sequence detection system. The TBP (TATA box binding protein) gene was used as internal control (primers sequences are available upon request). Relative expression (R) was then calculated with the DCT method 1 .
Western blot
Proliferating myoblasts and differentiated myotubes were washed twice in PBS, and incubated in 100 ml of 10 mM Tris (pH 6.8), 1 mM EDTA, proteinase inhibitor cocktail (Roche; Basel, Switzerland) for 15 min on ice. 10 ml of 10% SDS were added to each well, cells were mechanically broken with a cell scraper, and the protein lysate was vortexed and passed through a pipette tip. Protein concentration was determined with BCA Protein Assay Kit (Thermo Scientific-Pierce; Waltham, Massachusetts, USA) and 20 mg of protein per sample were loaded onto 10% or 12% glycine-tris large-sized acrylamide gels. Proteins were blotted onto a 0.45 lm nitrocellulose membrane (GE Healthcare; Waukesha, WI, USA) in transfer buffer. Membranes were saturated in 5% TBST milk at room temperature for 1 h and incubated with goat polyclonal anti-OPN antibody (O3389, 1:500; Sigma-Aldrich, St. Louis, MO, USA) or mouse monoclonal anti-actin antibody (MAB1501, 1:5.000; Millipore; Billerica, MA, USA) in 5% TBST milk at 4 C overnight.
Appropriate secondary HRP-conjugated antibodies were used and bands were visualized by enhanced chemiluminescence (Millipore; Billerica, MA, USA 
Statistical analyses
Osteopontin expression was evaluated as four distinct outcomes: SPP1 mRNA evaluated by RT-PCR (normalized to TBP expression); OPN protein expression evaluated by densitometry of the 50 kDa Western blot band; OPN protein expression evaluated by densitometry of the 55 kDa Western blot band; and OPN protein evaluated by densitometry of the two bands combined. All Western blot intensities were normalized to ACTB band intensity. The following variables, pertaining to patients from whom original muscle biopsies were obtained, were used to group corresponding primary cell cultures: DMD patient vs. healthy control, and rs28357094 genotype (TT vs. TG). Due to the relative rarity of the homozygous GG genotype, it was not possible to obtain a sufficient number of GG cultures for a meaningful statistical comparison, so these were not included in this study. However, the TT to TG comparison may be considered adequate in the light of the dominant effect of the rs28357094 SNP described in DMD (2) . Outcome differences between groups were compared with the Mann-Whitney U test. Outcome changes within groups after myotube differentiation were evaluated by paired Wilcoxon test, while outcome changes within groups with increasing concentrations of DFZ were evaluated by repeated measures ANOVA. Independent and concurrent effects of biopsy variables (dystrophin deficiency and rs28357094 genotype as categorical variables) and DFZ concentration (as a quantitative variable), as well as of their interactions, were evaluated in repeated measures ANCOVA models, distinctly for myoblast and differentiated myotube cultures. Statistical significance was set at P < 0.05.
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